NTRK1 Fusion Positive

What is NTRK1 Fusion Positive?

NTRK1 Fusion Positive is an alteration of the NTRK1 gene. This alteration, or alteration of this gene, is found in some types of cancer. It occurs when the NTRK1 gene fuses with other genes in the tumor cells, leading to increased gene activity. NTRK1 gene fusions result in the unchecked growth and spread of cancer cells, leading to aggressive wide-spread tumors.

Types of Cancers Associated with NTRK1 Fusion Positive

NTRK1 Fusion Positive has been seen in numerous tumor types, although some are more commonly seen than others. These tumors include:

  • Soft tissue sarcomas
  • Secretory carcinoma
  • Gastrointestinal stromal tumors
  • Salivary gland carcinoma
  • Papillary thyroid carcinoma
  • Lung carcinoma
  • Breast carcinoma
  • Cholangiocarcinoma
  • Uterine tumors

Implications of an NTRK1 Fusion Positive Diagnosis

A diagnosis of NTRK1 Fusion Positive is associated with a worse prognosis than other tumor types. The increased activity of the NTRK1 gene is linked to deadlier, faster-spreading tumors, making treatment more difficult and less successful. NTRK1 Fusion Positive patients have been treated with Locoregional surgical resection combined with radiation and chemotherapy. This results in a higher risk of recurrence for these patients.

Targeted Therapies for NTRK1 Fusion Positive

In recent years, targeted therapies have become a common treatment for cancers associated with NTRK1 Fusion Positive. These therapies focus on specific changes in cancer cells, such as alterations to the NTRK1 gene. In the case of NTRK1 Fusion Positive, targeted therapies include drugs that target the protein produced by NTRK1 alterations. These drugs interfere with the protein’s ability to drive the unchecked growth of tumor cells.